Sugi Predict

Sugi Predict / Compounds / SCHEMBL1922183

SCHEMBL1922183

SCHEMBL1922183

CCc1nn2c(-c3ccc(Cl)cc3Cl)c(C)oc2c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MARS1 P56192 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ GPR55 Q9Y2T6 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ DPP4 P27487 8/20 0.39
▸ DPP8 Q6V1X1 1/20 0.38
▸ CRHR1 P34998 2/20 0.38
▸ FABP3 P05413 1/20 0.37
▸ FABP4 P15090 1/20 0.37
▸ FABP5 Q01469 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922346 0.89 MAPT (0.46) LMNAMAPTSMN1; SMN2GAAHTT
SCHEMBL2255533 0.87 CRHR1 (0.37) LMNAMAPTSMN1; SMN2GAAHTT
SCHEMBL1922297 0.86 LMNA (0.48) MARS1LMNAMAPTHTTKMT2A
SCHEMBL1922326 0.86 NPC1 (0.45) LMNAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL1922248 0.85 GPBAR1 (0.45) SMN1; SMN2DPP4DPP8CRHR1TSHR
SCHEMBL1922608 0.85 NPC1 (0.46) LMNAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL1922932 0.84 SMN1; SMN2 (0.48) LMNAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL1922628 0.84 DPP4 (0.42) SMN1; SMN2KMT2ADPP4DPP8POLB
SCHEMBL1923712 0.83 DPP4 (0.39) KMT2ADPP4DPP8NPC1TSHR
SCHEMBL2256612 0.83 NPC1 (0.49) LMNAMAPTSMN1; SMN2KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 MARS1 1260/4885LMNA 4856/4885MAPT 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.